Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:26:28.831Z.
Calculation as of: 2026-10-06T15:26:28.831Z.
Quote observation: 2026-10-06T15:25:31.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8c517f571e23d8c9640577b72a0d01a1674ca2fb527f0620093024032568825b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$5.26B
EV/EBITDA Ratio
N/A
TTM Avg
12.99x
3Y Avg
275.14x
5Y Avg
275.14x
Market Cap
$5.23B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.08B
EV/EBITDA Ratio
16.16x
TTM Avg
15.97x
3Y Avg
19.93x
5Y Avg
21.74x
Market Cap
$5.54B
EV/EBITDA Ratio
30.79x
TTM Avg
33.01x
3Y Avg
33.01x
5Y Avg
33.01x
Market Cap
$4.91B
EV/EBITDA Ratio
N/A
TTM Avg
2239.52x
3Y Avg
2239.52x
5Y Avg
2239.52x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | $5.25B | N/A | N/A | N/A | N/A |
| CRISPR Therapeutics AG (CRSP)vs › | $5.26B | N/A | 12.99x | 275.14x | 275.14x |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.23B | N/A | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.36B | 24.10x | 26.05x | 37.20x | 51.94x |
| Erasca, Inc. (ERAS)vs › | $5.10B | N/A | N/A | N/A | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.08B | 16.16x | 15.97x | 19.93x | 21.74x |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.54B | 30.79x | 33.01x | 33.01x | 33.01x |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.91B | N/A | 2239.52x | 2239.52x | 2239.52x |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.89B | N/A | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.86B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
